Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 clinical trial evaluating ODM-212 in combination with standard of care treatments in patients with advanced solid tumours.

Next Previous
Trial Profile

A Phase 1b/2 clinical trial evaluating ODM-212 in combination with standard of care treatments in patients with advanced solid tumours.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; ODM-212 (Primary) ; Paclitaxel (Primary) ; Sotorasib (Primary)
  • Indications Adenocarcinoma; Mesothelioma; Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TEADCO
  • Sponsors Orion Pharma

Most Recent Events

  • 06 May 2026 New trial record
  • 23 Apr 2026 According to Orion Pharma media release, announced the initiation of a Phase 1b/2 basket trial evaluating ODM-212, a potential best-in-class, oral pan-TEAD inhibitor, in combination with standard of care treatments in Solid tumors..

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top